Parnax Lab share price, P/E, ROE & financials

On 6 Nov 2026, Parnax Lab was priced at ₹103.14, or 13.2× trailing earnings, against an industry P/E of 28.7×, and the shares are 31% below their 52-week high. Sales and net profit grew 14% and 11% a year over 3 years, with ROCE of 16% and ROE of 13%. Debt is 0.87× equity. It is a small-cap company with a market cap of ₹118 Cr, ranked 115th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 15% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹110.70
Day high: ₹110.70
Day low: ₹100.25
Prev. close: ₹104.00
Volume: 176

Health check

1 good · 3 fair · 2 to check

ReturnsBehind
−14.8% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 13.2 vs industry 28.7.
GrowthSteady
Sales +14.0%, profit +11.0% a year over 3 years.
ProfitabilityAverage
ROCE 16.3% vs peer median 17.9%.
Balance sheetFair
Debt 0.87× equity, interest covered 3.9×, Piotroski 4 of 9.
Red flags2 to check
Quarterly profit down 87.0% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹118 Cr, #115 of 154 in its industry by size.

Defensive

Beta 0.20 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹252 Cr · profit ₹9 Cr

Market cap: ₹118 Cr; Small cap
P/E: 13.2; Industry 28.7
Price to book: 1.24; Peers 4.99
Dividend yield: 0.00%
ROE: 13.2%; Peers 14.7%
ROCE: 16.3%; Peers 17.9%
Debt to equity: 0.87; Debt ₹83 Cr
EPS (TTM): ₹7.79; Face value ₹10
OPM (TTM): 9.6%; Net margin 3.5%
Sales growth: +6.4%; Latest quarter vs a year ago
Profit growth: −87.0%; Latest quarter vs a year ago
Price to sales: 0.47; EV/EBITDA 8.2

Strengths

P/E of 13.2 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly profit down 87.0% on a year ago.
31% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products. It also provides oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics,…

Headquarters: Mumbai
Employees: 12
Sector: Healthcare
ISIN: INE383L01019
Website: naxparlab.com

Price range

52 weeks

₹90.00₹149.50

Today

₹100.25₹110.70

Avg volume (3M): 4K
1-year return: minus 14.8%
From 52-week high: minus 31.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.87%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.30%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.81%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.59%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.93%	minus 6.6%
PARNAXLABParnax Lab	103.14	minus 0.83%	118	13.2	1.24	16.3%	13.2%	9.6%	14.0%	11.0%	0.00%	minus 14.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.59%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
53.4	62.6	62.9	69.6	56.8
45.9	54.5	56.1	64.7	52.5
7.4	8.1	6.9	4.9	4.3
13.9%	12.9%	10.9%	7.0%	7.6%
0.2	0.6	1	2	0.2
1.2	1.4	1.5	1.6	1.6
1.9	2.1	2	2	2.2
–	–	−1.1	−0.2	–
4.5	5.2	3.3	3	0.6
26.5%	30.4%	16.4%	27.2%	28.6%
3.3	3.6	2.7	2.2	0.4
2.85	3.15	2.37	1.90	0.37

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +14.0%
Profit CAGR 3Y: +11.0%
EPS CAGR 3Y: +9.7%
ROE: 13.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
168	189	188	249
–	+12.6%	minus 0.5%	+32.4%
144	165	161	217
23.3	23.6	27.2	31.6
13.9%	12.5%	14.5%	12.7%
0.7	0.6	1.4	1.8
4.9	5.3	5.2	5.5
6.5	7	7.4	8
−0.3	0.1	−0.3	−3.8
12.3	12	15.7	15.9
29.7%	20.1%	26.4%	25.8%
8.6	9.6	11.5	11.8
–	+11.5%	+19.9%	+2.2%
7.79	8.37	10.05	10.27

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
11.5	11.5	11.5	11.5
50.7	60.1	71.6	83.6
54.7	80.6	69.5	82.8
28.2	38.1	37.2	49.7
145	190	190	228
83	112	120	133
6.5	23	32.3	19
0.2	0.2	0.2	0.2
1.3	0.5	2.7	2.3
54.1	54.9	34.9	73.1
145	190	190	228

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
20.9	15.9	32.3	8
−9.9	−31.5	−16.4	−16.4
−14.1	14.8	−15.8	8.2
−3.1	−0.8	0.1	−0.2
−11.3	−32.5	−18.6	−35.5
9.6	−16.6	13.7	−27.5

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you